Last Updated: October 1, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

United States: These 64 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Generic Entry Dates in Other Countries

African Regional IP Organization (ARIPO) Argentina Australia Austria Brazil Canada Chile China Colombia Costa Rica Croatia Cuba Cyprus Denmark Dominican Republic Ecuador Eurasian Patent Organization European Patent Office Finland France Georgia, Republic of Germany Guatemala Honduras Hong Kong Hungary Israel Italy Japan Jordan Lithuania Luxembourg Malaysia Mexico Montenegro Morocco Netherlands New Zealand Nicaragua Norway Panama Peru Philippines Poland Portugal Russian Federation San Marino Saudi Arabia Serbia Singapore Slovenia South Africa South Korea Spain Taiwan Tunisia Turkey Ukraine United Kingdom Uruguay
Preferred citation:
Friedman, Yali, "United States: These 64 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can VEREGEN (sinecatechins) generic drug versions launch in the United States?

Generic name: sinecatechins
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 02, 2026
Generic Entry Controlled by: United States Patent Patent 5,795,911

Drug Price Trends for VEREGEN
VEREGEN is a drug marketed by Ani Pharms. There is one patent protecting this drug. There has been litigation on patents covering VEREGEN

See drug price trends for VEREGEN.

The generic ingredient in VEREGEN is sinecatechins. Additional details are available on the sinecatechins profile page.

When can SCENESSE (afamelanotide) generic drug versions launch in the United States?

Generic name: afamelanotide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 08, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

SCENESSE is a drug marketed by Clivunel Inc. There is one patent protecting this drug.

See drug price trends for SCENESSE.

The generic ingredient in SCENESSE is afamelanotide. Additional details are available on the afamelanotide profile page.

When can ADASUVE (loxapine) generic drug versions launch in the United States?

Generic name: loxapine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 23, 2026
Generic Entry Controlled by: United States Patent Patent 8,387,612

ADASUVE is a drug marketed by Nova Pneuma. There is one patent protecting this drug. There has been litigation on patents covering ADASUVE

See drug price trends for ADASUVE.

The generic ingredient in ADASUVE is loxapine. Additional details are available on the loxapine profile page.

When can SYNRIBO (omacetaxine mepesuccinate) generic drug versions launch in the United States?

Generic name: omacetaxine mepesuccinate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 26, 2026
Generic Entry Controlled by: United States Patent Patent 6,987,103

SYNRIBO is a drug marketed by Teva Pharms Intl. There is one patent protecting this drug and one Paragraph IV challenge.

See drug price trends for SYNRIBO.

The generic ingredient in SYNRIBO is omacetaxine mepesuccinate. Additional details are available on the omacetaxine mepesuccinate profile page.

When can XEGLYZE (abametapir) generic drug versions launch in the United States?

Generic name: abametapir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 28, 2026
Generic Entry Controlled by: United States Patent Patent 7,812,163

XEGLYZE is a drug marketed by Lnhc. There are two patents protecting this drug.

The generic ingredient in XEGLYZE is abametapir. Additional details are available on the abametapir profile page.

When can BEVYXXA (betrixaban) generic drug versions launch in the United States?

Generic name: betrixaban
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: United States Patent Patent 7,598,276

BEVYXXA is a drug marketed by Portola Pharms Inc. There are five patents protecting this drug. There has been litigation on patents covering BEVYXXA

See drug price trends for BEVYXXA.

The generic ingredient in BEVYXXA is betrixaban. Additional details are available on the betrixaban profile page.

When can EXPAREL (bupivacaine) generic drug versions launch in the United States?

Generic name: bupivacaine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 09, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

EXPAREL is a drug marketed by Pacira Pharms Inc. There are twenty-one patents protecting this drug. There has been litigation on patents covering EXPAREL

See drug price trends for EXPAREL.

The generic ingredient in EXPAREL is bupivacaine. Additional details are available on the bupivacaine profile page.

When can HORIZANT (gabapentin enacarbil) generic drug versions launch in the United States?

Generic name: gabapentin enacarbil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 10, 2026
Generic Entry Controlled by: United States Patent Patent 8,026,279

HORIZANT is a drug marketed by Azurity. There are three patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering HORIZANT

See drug price trends for HORIZANT.

The generic ingredient in HORIZANT is gabapentin enacarbil. Additional details are available on the gabapentin enacarbil profile page.

When can IZERVAY (avacincaptad pegol sodium) generic drug versions launch in the United States?

Generic name: avacincaptad pegol sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 11, 2026
Generic Entry Controlled by: United States Patent Patent 8,236,773

IZERVAY is a drug marketed by Astellas. There are six patents protecting this drug.

See drug price trends for IZERVAY.

The generic ingredient in IZERVAY is avacincaptad pegol sodium. Additional details are available on the avacincaptad pegol sodium profile page.

When can GIVLAARI (givosiran sodium) generic drug versions launch in the United States?

Generic name: givosiran sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

GIVLAARI is a drug marketed by Alnylam Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering GIVLAARI

See drug price trends for GIVLAARI.

The generic ingredient in GIVLAARI is givosiran sodium. Additional details are available on the givosiran sodium profile page.

When can AXUMIN (fluciclovine f-18) generic drug versions launch in the United States?

Generic name: fluciclovine f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: United States Patent Patent 10,010,632

AXUMIN is a drug marketed by Blue Earth. There are eight patents protecting this drug. There has been litigation on patents covering AXUMIN

The generic ingredient in AXUMIN is fluciclovine f-18. Additional details are available on the fluciclovine f-18 profile page.

When can ZUNVEYL (benzgalantamine gluconate) generic drug versions launch in the United States?

Generic name: benzgalantamine gluconate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 01, 2026
Generic Entry Controlled by: United States Patent Patent 9,763,953

ZUNVEYL is a drug marketed by Alpha Cognition. There are four patents protecting this drug. There has been litigation on patents covering ZUNVEYL

The generic ingredient in ZUNVEYL is benzgalantamine gluconate. Additional details are available on the benzgalantamine gluconate profile page.

When can VYONDYS 53 (golodirsen) generic drug versions launch in the United States?

Generic name: golodirsen
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

VYONDYS 53 is a drug marketed by Sarepta Theraps Inc. There is one patent protecting this drug. There has been litigation on patents covering VYONDYS 53

The generic ingredient in VYONDYS 53 is golodirsen. Additional details are available on the golodirsen profile page.

When can SIGNIFOR (pasireotide diaspartate) generic drug versions launch in the United States?

Generic name: pasireotide diaspartate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 14, 2026
Generic Entry Controlled by: United States Patent Patent 7,473,761

SIGNIFOR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR.

The generic ingredient in SIGNIFOR is pasireotide diaspartate. Additional details are available on the pasireotide diaspartate profile page.

When can VYNDAMAX (tafamidis) generic drug versions launch in the United States?

Generic name: tafamidis
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2026
Generic Entry Controlled by: United States Patent Patent 7,214,695

VYNDAMAX is a drug marketed by Foldrx Pharms. There are three patents protecting this drug. There has been litigation on patents covering VYNDAMAX

See drug price trends for VYNDAMAX.

The generic ingredient in VYNDAMAX is tafamidis. Additional details are available on the tafamidis profile page.

When can VYNDAQEL (tafamidis meglumine) generic drug versions launch in the United States?

Generic name: tafamidis meglumine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2026
Generic Entry Controlled by: United States Patent Patent 7,214,695

VYNDAQEL is a drug marketed by Foldrx Pharms. There are two patents protecting this drug. There has been litigation on patents covering VYNDAQEL

See drug price trends for VYNDAQEL.

The generic ingredient in VYNDAQEL is tafamidis meglumine. Additional details are available on the tafamidis meglumine profile page.

When can EPANOVA (omega-3-carboxylic acids) generic drug versions launch in the United States?

Generic name: omega-3-carboxylic acids
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 20, 2026
Generic Entry Controlled by: United States Patent Patent 7,960,370

EPANOVA is a drug marketed by Astrazeneca. There are four patents protecting this drug.

The generic ingredient in EPANOVA is omega-3-carboxylic acids. Additional details are available on the omega-3-carboxylic acids profile page.

When can TISSUEBLUE (brilliant blue g) generic drug versions launch in the United States?

Generic name: brilliant blue g
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 20, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

TISSUEBLUE is a drug marketed by Dutch Ophthalmic.

The generic ingredient in TISSUEBLUE is brilliant blue g. Additional details are available on the brilliant blue g profile page.

When can SYMTUZA (cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate) generic drug versions launch in the United States?

Generic name: cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 26, 2026
Generic Entry Controlled by: United States Patent Patent 7,700,645

Drug Price Trends for SYMTUZA
SYMTUZA is a drug marketed by Janssen Prods. There are six patents protecting this drug. There has been litigation on patents covering SYMTUZA

See drug price trends for SYMTUZA.

The generic ingredient in SYMTUZA is cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate. Additional details are available on the cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate profile page.

When can VIBATIV (telavancin hydrochloride) generic drug versions launch in the United States?

Generic name: telavancin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 01, 2027
Generic Entry Controlled by: United States Patent Patent 7,531,623

VIBATIV is a drug marketed by Apotex. There is one patent protecting this drug.

See drug price trends for VIBATIV.

The generic ingredient in VIBATIV is telavancin hydrochloride. Additional details are available on the telavancin hydrochloride profile page.

When can PIQRAY (alpelisib) generic drug versions launch in the United States?

Generic name: alpelisib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 18, 2027
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

PIQRAY is a drug marketed by Novartis. There are two patents protecting this drug.

See drug price trends for PIQRAY.

The generic ingredient in PIQRAY is alpelisib. Additional details are available on the alpelisib profile page.

When can STIOLTO RESPIMAT (olodaterol hydrochloride; tiotropium bromide) generic drug versions launch in the United States?

Generic name: olodaterol hydrochloride; tiotropium bromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 19, 2027
Generic Entry Controlled by: United States Patent Patent 7,727,984

STIOLTO RESPIMAT is a drug marketed by Boehringer Ingelheim. There are five patents protecting this drug. There has been litigation on patents covering STIOLTO RESPIMAT

See drug price trends for STIOLTO RESPIMAT.

The generic ingredient in STIOLTO RESPIMAT is olodaterol hydrochloride; tiotropium bromide. Additional details are available on the olodaterol hydrochloride; tiotropium bromide profile page.

When can STRIVERDI RESPIMAT (olodaterol hydrochloride) generic drug versions launch in the United States?

Generic name: olodaterol hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 19, 2027
Generic Entry Controlled by: United States Patent Patent 7,727,984

STRIVERDI RESPIMAT is a drug marketed by Boehringer Ingelheim. There is one patent protecting this drug. There has been litigation on patents covering STRIVERDI RESPIMAT

See drug price trends for STRIVERDI RESPIMAT.

The generic ingredient in STRIVERDI RESPIMAT is olodaterol hydrochloride. Additional details are available on the olodaterol hydrochloride profile page.

When can KYNAMRO (mipomersen sodium) generic drug versions launch in the United States?

Generic name: mipomersen sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 29, 2027
Generic Entry Controlled by: United States Patent Patent 7,511,131

KYNAMRO is a drug marketed by Kastle Theraps Llc. There is one patent protecting this drug. There has been litigation on patents covering KYNAMRO

See drug price trends for KYNAMRO.

The generic ingredient in KYNAMRO is mipomersen sodium. Additional details are available on the mipomersen sodium profile page.

When can LEGUBETI (acetylcysteine lysine) generic drug versions launch in the United States?

Generic name: acetylcysteine lysine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 13, 2027
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

LEGUBETI is a drug marketed by Galephar.

The generic ingredient in LEGUBETI is acetylcysteine lysine. Additional details are available on the acetylcysteine lysine profile page.

When can ADVIL ALLERGY SINUS (chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride) generic drug versions launch in the United States?

Generic name: chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2027
Generic Entry Controlled by: United States Patent Patent 7,863,287

ADVIL ALLERGY SINUS is a drug marketed by Haleon Us Holdings. There is one patent protecting this drug.

The generic ingredient in ADVIL ALLERGY SINUS is chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride. Additional details are available on the chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride profile page.

When can DUAVEE (bazedoxifene acetate; estrogens, conjugated) generic drug versions launch in the United States?

Generic name: bazedoxifene acetate; estrogens, conjugated
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 10, 2027
Generic Entry Controlled by: United States Patent Patent 7,683,051

Drug Price Trends for DUAVEE
DUAVEE is a drug marketed by Wyeth Pharms. There is one patent protecting this drug.

See drug price trends for DUAVEE.

The generic ingredient in DUAVEE is bazedoxifene acetate; estrogens, conjugated. Additional details are available on the bazedoxifene acetate; estrogens, conjugated profile page.

When can LIVMARLI (maralixibat chloride) generic drug versions launch in the United States?

Generic name: maralixibat chloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 13, 2027
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

LIVMARLI is a drug marketed by Mirum. There are ten patents protecting this drug. There has been litigation on patents covering LIVMARLI

See drug price trends for LIVMARLI.

The generic ingredient in LIVMARLI is maralixibat chloride. Additional details are available on the maralixibat chloride profile page.

When can AVEED (testosterone undecanoate) generic drug versions launch in the United States?

Generic name: testosterone undecanoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 14, 2027
Generic Entry Controlled by: United States Patent Patent 7,718,640

AVEED is a drug marketed by Endo Operations. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering AVEED

See drug price trends for AVEED.

The generic ingredient in AVEED is testosterone undecanoate. Additional details are available on the testosterone undecanoate profile page.

When can DYANAVEL XR 10 (amphetamine; amphetamine aspartate/dextroamphetamine sulfate) generic drug versions launch in the United States?

Generic name: amphetamine; amphetamine aspartate/dextroamphetamine sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2027
Generic Entry Controlled by: United States Patent Patent 8,747,902

DYANAVEL XR 10 is a drug marketed by Tris Pharma Inc. There are five patents protecting this drug.

The generic ingredient in DYANAVEL XR 10 is amphetamine; amphetamine aspartate/dextroamphetamine sulfate. Additional details are available on the amphetamine; amphetamine aspartate/dextroamphetamine sulfate profile page.

When can VICTRELIS (boceprevir) generic drug versions launch in the United States?

Generic name: boceprevir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 17, 2027
Generic Entry Controlled by: United States Patent Patent 8,119,602

VICTRELIS is a drug marketed by Merck Sharp Dohme. There are two patents protecting this drug.

The generic ingredient in VICTRELIS is boceprevir. Additional details are available on the boceprevir profile page.

When can VARUBI (rolapitant hydrochloride) generic drug versions launch in the United States?

Generic name: rolapitant hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 04, 2027
Generic Entry Controlled by: United States Patent Patent 8,178,550

VARUBI is a drug marketed by Tersera. There are eight patents protecting this drug.

The generic ingredient in VARUBI is rolapitant hydrochloride. Additional details are available on the rolapitant hydrochloride profile page.

When can SAVAYSA (edoxaban tosylate) generic drug versions launch in the United States?

Generic name: edoxaban tosylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 18, 2027
Generic Entry Controlled by: United States Patent Patent 7,365,205

Drug Price Trends for SAVAYSA
SAVAYSA is a drug marketed by Daiichi Sankyo Inc. There are two patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering SAVAYSA

See drug price trends for SAVAYSA.

The generic ingredient in SAVAYSA is edoxaban tosylate. Additional details are available on the edoxaban tosylate profile page.

When can CHLORAPREP ONE-STEP (chlorhexidine gluconate; isopropyl alcohol) generic drug versions launch in the United States?

Generic name: chlorhexidine gluconate; isopropyl alcohol
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 25, 2027
Generic Entry Controlled by: United States Patent Patent 7,422,388

CHLORAPREP ONE-STEP is a drug marketed by Becton Dickinson Co.

The generic ingredient in CHLORAPREP ONE-STEP is chlorhexidine gluconate; isopropyl alcohol. Additional details are available on the chlorhexidine gluconate; isopropyl alcohol profile page.

When can GENVOYA (cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate) generic drug versions launch in the United States?

Generic name: cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 26, 2027
Generic Entry Controlled by: United States Patent Patent 8,981,103

GENVOYA is a drug marketed by Gilead Sciences Inc. There are nine patents protecting this drug. There has been litigation on patents covering GENVOYA

See drug price trends for GENVOYA.

The generic ingredient in GENVOYA is cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate. Additional details are available on the cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate profile page.

When can STRIBILD (cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate) generic drug versions launch in the United States?

Generic name: cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 26, 2027
Generic Entry Controlled by: United States Patent Patent 8,981,103

STRIBILD is a drug marketed by Gilead Sciences Inc. There are seven patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering STRIBILD

See drug price trends for STRIBILD.

The generic ingredient in STRIBILD is cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate. Additional details are available on the cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate profile page.

When can VITEKTA (elvitegravir) generic drug versions launch in the United States?

Generic name: elvitegravir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 26, 2027
Generic Entry Controlled by: United States Patent Patent 8,981,103

VITEKTA is a drug marketed by Gilead Sciences Inc. There are three patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering VITEKTA

The generic ingredient in VITEKTA is elvitegravir. Additional details are available on the elvitegravir profile page.

When can AMYVID (florbetapir f-18) generic drug versions launch in the United States?

Generic name: florbetapir f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 30, 2027
Generic Entry Controlled by: United States Patent Patent 7,687,052

AMYVID is a drug marketed by Avid Radiopharms Inc. There are two patents protecting this drug. There has been litigation on patents covering AMYVID

The generic ingredient in AMYVID is florbetapir f-18. Additional details are available on the florbetapir f-18 profile page.

When can VELTASSA (patiromer sorbitex calcium) generic drug versions launch in the United States?

Generic name: patiromer sorbitex calcium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 29, 2027
Generic Entry Controlled by: United States Patent Patent 8,282,913

Drug Price Trends for VELTASSA
VELTASSA is a drug marketed by Vifor Pharma. There are seven patents protecting this drug. There has been litigation on patents covering VELTASSA

See drug price trends for VELTASSA.

The generic ingredient in VELTASSA is patiromer sorbitex calcium. Additional details are available on the patiromer sorbitex calcium profile page.

When can CONTRAVE (bupropion hydrochloride; naltrexone hydrochloride) generic drug versions launch in the United States?

Generic name: bupropion hydrochloride; naltrexone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 04, 2027
Generic Entry Controlled by: United States Patent Patent 9,107,837

CONTRAVE is a drug marketed by Azurity. There are eighteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering CONTRAVE

See drug price trends for CONTRAVE.

The generic ingredient in CONTRAVE is bupropion hydrochloride; naltrexone hydrochloride. Additional details are available on the bupropion hydrochloride; naltrexone hydrochloride profile page.

When can EMBEDA (morphine sulfate; naltrexone hydrochloride) generic drug versions launch in the United States?

Generic name: morphine sulfate; naltrexone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: United States Patent Patent 8,158,156

EMBEDA is a drug marketed by Alpharma Pharms. There are seven patents protecting this drug and four Paragraph IV challenges.

See drug price trends for EMBEDA.

The generic ingredient in EMBEDA is morphine sulfate; naltrexone hydrochloride. Additional details are available on the morphine sulfate; naltrexone hydrochloride profile page.

When can SIRTURO (bedaquiline fumarate) generic drug versions launch in the United States?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can PREZCOBIX (cobicistat; darunavir) generic drug versions launch in the United States?

Generic name: cobicistat; darunavir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 26, 2027
Generic Entry Controlled by: United States Patent Patent 7,700,645

Drug Price Trends for PREZCOBIX
PREZCOBIX is a drug marketed by Janssen Prods. There are three patents protecting this drug. There has been litigation on patents covering PREZCOBIX

See drug price trends for PREZCOBIX.

The generic ingredient in PREZCOBIX is cobicistat; darunavir. Additional details are available on the cobicistat; darunavir profile page.

When can PARAGARD T 380A (copper) generic drug versions launch in the United States?

Generic name: copper
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2027
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

PARAGARD T 380A is a drug marketed by Coopersurgical.

The generic ingredient in PARAGARD T 380A is copper. Additional details are available on the copper profile page.

When can DOJOLVI (triheptanoin) generic drug versions launch in the United States?

Generic name: triheptanoin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 30, 2027
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

DOJOLVI is a drug marketed by Ultragenyx Pharm Inc. There are two patents protecting this drug. There has been litigation on patents covering DOJOLVI

See drug price trends for DOJOLVI.

The generic ingredient in DOJOLVI is triheptanoin. Additional details are available on the triheptanoin profile page.

When can PICATO (ingenol mebutate) generic drug versions launch in the United States?

Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 06, 2027
Generic Entry Controlled by: United States Patent Patent 8,278,292

Drug Price Trends for PICATO
PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PICATO

See drug price trends for PICATO.

The generic ingredient in PICATO is ingenol mebutate. Additional details are available on the ingenol mebutate profile page.

When can BYFAVO (remimazolam besylate) generic drug versions launch in the United States?

Generic name: remimazolam besylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: United States Patent Patent 9,777,007

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. Additional details are available on the remimazolam besylate profile page.

When can EPIDIOLEX (cannabidiol) generic drug versions launch in the United States?

Generic name: cannabidiol
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 31, 2027
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

EPIDIOLEX is a drug marketed by Jazz Pharms Res. There are thirty-three patents protecting this drug. There has been litigation on patents covering EPIDIOLEX

See drug price trends for EPIDIOLEX.

The generic ingredient in EPIDIOLEX is cannabidiol. Additional details are available on the cannabidiol profile page.

When can RELISTOR (methylnaltrexone bromide) generic drug versions launch in the United States?

Generic name: methylnaltrexone bromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: United States Patent Patent 12,303,592

Drug Price Trends for RELISTOR
RELISTOR is a drug marketed by Salix Pharms and SalixThere are twelve patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering RELISTOR

See drug price trends for RELISTOR.

The generic ingredient in RELISTOR is methylnaltrexone bromide. Additional details are available on the methylnaltrexone bromide profile page.

When can LAMPIT (nifurtimox) generic drug versions launch in the United States?

Generic name: nifurtimox
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 06, 2027
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

LAMPIT is a drug marketed by Bayer Healthcare.

See drug price trends for LAMPIT.

The generic ingredient in LAMPIT is nifurtimox. Additional details are available on the nifurtimox profile page.

When can LYNPARZA (olaparib) generic drug versions launch in the United States?

Generic name: olaparib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 12, 2027
Generic Entry Controlled by: United States Patent Patent 8,143,241

LYNPARZA is a drug marketed by Astrazeneca. There are twelve patents protecting this drug. Three tentatively approved generics are ready to enter the market. There has been litigation on patents covering LYNPARZA

See drug price trends for LYNPARZA.

The generic ingredient in LYNPARZA is olaparib. Additional details are available on the olaparib profile page.

When can VISTOGARD (uridine triacetate) generic drug versions launch in the United States?

Generic name: uridine triacetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 17, 2027
Generic Entry Controlled by: United States Patent Patent 7,776,838

VISTOGARD is a drug marketed by Btg Intl. There is one patent protecting this drug.

See drug price trends for VISTOGARD.

The generic ingredient in VISTOGARD is uridine triacetate. Additional details are available on the uridine triacetate profile page.

When can NOURIANZ (istradefylline) generic drug versions launch in the United States?

Generic name: istradefylline
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 05, 2027
Generic Entry Controlled by: United States Patent Patent 8,318,201

NOURIANZ is a drug marketed by Kyowa Kirin. There are two patents protecting this drug. There has been litigation on patents covering NOURIANZ

See drug price trends for NOURIANZ.

The generic ingredient in NOURIANZ is istradefylline. Additional details are available on the istradefylline profile page.

When can SOLOSEC (secnidazole) generic drug versions launch in the United States?

Generic name: secnidazole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 15, 2027
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

Drug Price Trends for SOLOSEC
SOLOSEC is a drug marketed by Evofem Inc. There are eleven patents protecting this drug. There has been litigation on patents covering SOLOSEC

See drug price trends for SOLOSEC.

The generic ingredient in SOLOSEC is secnidazole. Additional details are available on the secnidazole profile page.

When can TYMLOS (abaloparatide) generic drug versions launch in the United States?

Generic name: abaloparatide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 03, 2027
Generic Entry Controlled by: United States Patent Patent 8,748,382

Drug Price Trends for TYMLOS
TYMLOS is a drug marketed by Radius. There are nine patents protecting this drug. There has been litigation on patents covering TYMLOS

See drug price trends for TYMLOS.

The generic ingredient in TYMLOS is abaloparatide. Additional details are available on the abaloparatide profile page.

When can BELEODAQ (belinostat) generic drug versions launch in the United States?

Generic name: belinostat
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 27, 2027
Generic Entry Controlled by: United States Patent Patent 8,835,501

BELEODAQ is a drug marketed by Acrotech Biopharma. There are two patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering BELEODAQ

See drug price trends for BELEODAQ.

The generic ingredient in BELEODAQ is belinostat. Additional details are available on the belinostat profile page.

When can PYLARIFY (piflufolastat f-18) generic drug versions launch in the United States?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2027
Generic Entry Controlled by: United States Patent Patent 8,487,129

PYLARIFY is a drug marketed by Progenics Pharms Inc and AphelionThere are six patents protecting this drug.

See drug price trends for PYLARIFY.

The generic ingredient in PYLARIFY is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can PYLARIFY TRUVU (piflufolastat f-18) generic drug versions launch in the United States?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2027
Generic Entry Controlled by: United States Patent Patent 8,487,129

PYLARIFY TRUVU is a drug marketed by Aphelion. There are six patents protecting this drug.

The generic ingredient in PYLARIFY TRUVU is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can VARITHENA (polidocanol) generic drug versions launch in the United States?

Generic name: polidocanol
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 19, 2027
Generic Entry Controlled by: United States Patent Patent 7,814,943

VARITHENA is a drug marketed by Boston Scitfc. There are two patents protecting this drug.

See drug price trends for VARITHENA.

The generic ingredient in VARITHENA is polidocanol. Additional details are available on the polidocanol profile page.

When can ZOKINVY (lonafarnib) generic drug versions launch in the United States?

Generic name: lonafarnib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2027
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

ZOKINVY is a drug marketed by Sentynl Theraps Inc. There is one patent protecting this drug.

See drug price trends for ZOKINVY.

The generic ingredient in ZOKINVY is lonafarnib. Additional details are available on the lonafarnib profile page.

Last updated: May 12, 2026

United States Branded vs Generic Drug Markets Assessment and Regulatory Opportunities and Challenges

The US drug market is bifurcated: branded products still capture the majority of prescription spending, while generics dominate units dispensed and drive margin compression. The regulatory and patent landscape creates predictable windows for generic entry (Hatch-Waxman and Orange Book-driven Paragraph IV), but increasing complexity in exclusivity (new clinical investigations, method-of-use, and REMS-driven labeling constraints) and patent-structure expansion (multiple layers of formulation, process, and device-connected IP) raises barriers to rapid launches. Biologic and advanced therapy products add a parallel exclusivity and biosimilar pathway with different attack surfaces than small-molecule generics.

Market structure: what matters for licensing, investment, and entry strategy

Key US characteristics shape both branded pricing power and generic launch timing:

  • Spending mix: Branded drugs account for the largest share of US prescription drug spending; generics account for the largest share of units.
  • Unit economics: Generics typically win on price-per-treatment basis and substitution dynamics, but face tight margins in crowded segments.
  • Time to market: Generic profitability hinges on Paragraph IV timing, settlement terms, and ability to launch at high market share immediately after approval.
  • Regulatory friction: FDA review, labeling negotiations, and REMS/PMR alignment can delay commercialization even when patent barriers fall.
  • IP density: Many branded assets now carry large, layered patent estates covering polymorphs, salts, formulations, manufacturing, dosing regimens, and sometimes companion devices.

Where regulatory opportunity concentrates

  • Dry-powder/controlled-release/formulation: Opportunity is highest when Orange Book listings overreach or when patents are weak or not properly tied to the reference product.
  • Method-of-use and dosing regimen: Opportunities exist when generic labeling carveouts are practical and medical-meaningful dosing triggers can be achieved without infringement.
  • Manufacturing process patents: Atoms of value often move to process improvements that avoid method claims, or to non-infringing route/controls that support comparability.
  • Lifecycle renegotiation: Branded firms sometimes amend labeling and add patents near enforcement windows; generic firms can respond with faster, broader Paragraph IV challenges if the product-market fit is clear.

What drives branded drug revenue in the United States, and how do payers influence access?

Branded revenue durability is anchored by exclusivity length, clinical differentiation, reimbursement contracts, and limited therapeutic alternatives. Payers shape net realized prices through rebates, formulary placement, prior authorization, and specialty pharmacy tactics.

Branded durability levers

  • Clinical differentiation: Mechanism-of-action differentiation and durable safety narratives reduce formulary churn.
  • Contracting and rebate design: Indication-specific rebates, volume-based tiers, and formulary guarantees affect post-generic adoption economics.
  • Service-layer economics: Patient support, co-pay programs, and adherence programs can extend commercial effectiveness even after legal entry.
  • Label governance: Branded firms use labeling exclusivity and REMS structure to limit easy substitution in practice.

Access constraints that matter for generic uptake

  • Prior authorization: Slows switching after approval.
  • Step therapy: Requires sequential trial; reduces immediate generic penetration.
  • Specialty distribution: For high-cost oral or injectable branded products, distribution channels delay substitution.

How many patents protect US branded drugs, and why do patent estates increase entry risk?

For many high-revenue products, Orange Book patent families can exceed a handful of core composition-of-matter rights. Estates often include:

  • composition and solid-state form (polymorph/hydrate)
  • salts, solvates, or particle-size specifications
  • formulation (film coating, matrix system, extended-release matrix)
  • manufacturing process (steps, solvent system, crystallization conditions)
  • method-of-use and dosing regimens (therapeutic claims, titration schedules)

Patent estate complexity that changes generic strategy

  • Non-uniform claim coverage: A generic may avoid one claim while triggering others in the same or related patent.
  • Staggered expiry: Different patents expire on different dates, creating “whack-a-mole” entry.
  • Multiple Orange Book codes: Different patent types can map to different regulatory triggers.
  • Injunction leverage: Even narrow claim overlap can support injunctions that block launch.

What is the Orange Book status of key branded drugs, and how does it map to generic launch timing?

Orange Book status drives the Hatch-Waxman entry framework. For a generic applicant, launch timing depends on:

  • Listed patents for the reference listed drug (RLD)
  • Patent type (drug substance, drug product, use codes)
  • Exclusivity protections not listed as patents (three major categories: marketing exclusivity, orphan exclusivity, and pediatric exclusivity)

How Orange Book status translates to entry options

  • If patents expire: Generic approval can proceed at application approval time.
  • If patents are still in force: The applicant typically must file a Paragraph IV certification for each relevant listed patent to pursue an earlier launch (subject to litigation outcomes and settlement terms).
  • If patents are blocked: The applicant may delay launch until the earliest expiry date of an asserted patent or until exclusivity ends.

When does US FDA exclusivity prevent generic entry, and how can applicants design around it?

Exclusivity can extend beyond patent expiration and can block generic approvals or limit what labeling a generic can carry.

Exclusivity categories most likely to delay entry

  • New Chemical Entity (NCE) exclusivity: New active ingredient approvals.
  • New Molecular Entity (NME) marketing exclusivity: Similar concept under modern FDA framework depending on context.
  • 5-year new clinical investigation exclusivity: Requires qualifying clinical studies.
  • 7-year orphan exclusivity: For designated orphan uses.
  • 6-month pediatric exclusivity: Can extend patent life by six months when pediatric studies are completed and the pediatric exclusivity attaches to eligible patents.

Practical regulatory impacts on generic strategy

  • Label alignment: Generics must match the RLD for approved conditions of use unless a carveout can be legally supported.
  • Timing risk: Even successful Paragraph IV outcomes may not overcome marketing exclusivity barriers.
  • Segment selection: Generics may focus on indications not blocked by exclusivity where labeling pathways allow.

What Paragraph IV challenges succeed, and which factors predict settlement vs trial outcomes?

Paragraph IV challenges create market timing opportunities but depend on patent strength, evidence availability, and litigation posture. Outcomes often resolve through settlement agreements that set launch dates and payment structures.

Success predictors used in real-world litigation posture

  • Claim invalidity strength: Prior art and obviousness arguments that withstand summary judgment.
  • Written description and enablement: Weak specifications reduce enforcement.
  • Prosecution history: Estoppel and narrowing amendments.
  • Infringement fit: Whether the generic formulation method maps to claim limitations.
  • Device and method claims: More defenses can be built if generic labeling or formulation differs materially.

Settlement pattern that matters commercially

  • Authorized generic deals: Branded firms often secure an authorized generic launch through settlement, reducing generic entrant upside.
  • Launch-date scheduling: Settlement dates can compress or expand window of exclusivity for the challenger.
  • Scope caps: Settlements sometimes limit “at-risk” label claims or require compliance with carveouts.

How do generic labeling carveouts and FDA approval requirements shape “at-risk” launch?

Generics can win approval while preserving non-infringing labeling. The regulatory and commercial question becomes whether a carveout still supports meaningful substitution.

Label carveout realities that drive risk

  • Therapeutic equivalence: If carveout removes major indications, uptake drops.
  • Medical practice alignment: If switching clinicians prefer labeled therapy, off-label restrictions can slow adoption.
  • REMS: When REMS exists, labeling changes may require additional REMS elements or operational compliance.

What regulatory and patent barriers affect biologics and biosimilars differently than generics?

Biologics follow a different framework (BPCIA). Patent and exclusivity dynamics differ: fewer directly comparable “Orange Book patent type” constructs exist, and biosimilar litigation focuses on different exchange and timing rules.

Biosimilar-specific complexity

  • Comparability evidence: High evidentiary bar for structural and functional similarity.
  • Patent dance structure: Timing and exchange of information influence litigation schedules.
  • Interchangeability requirements: Not all biosimilars are interchangeable; substitution depends on state law and FDA designation.

Where the biosimilar opportunity concentrates

  • Mature biologics with expiring exclusivity
  • Switchability and payer contracting that rewards interchangeability
  • Manufacturing scale and cost-down that can support competitive pricing over time

How strong is the regulatory pathway for complex generics (NDAs to ANDAs, 505(b)(2))?

Complex generic products face higher regulatory burden than straightforward small-molecule generics. Two FDA pathways dominate:

  • ANDA for generics (with bioequivalence requirements)
  • 505(b)(2) for “bridge” development using some reliance on published literature or FDA-held data

Why complex generics are harder

  • Comparability: Formulation differences can affect pharmacokinetics and safety.
  • Suitability for generic substitution: Differentiated delivery systems can complicate interchangeability.
  • Higher risk of patent overlap: Formulation-specific and process-specific patents become more frequent.

What formulation and manufacturing IP blocks generic entry most often?

IP that most frequently blocks entry relates to product design and production. For formulation-heavy products:

  • polymorph/solid-state patents
  • particle size and distribution patents
  • release profile control for extended-release matrices
  • coating system and excipient-specific patents when tied to performance

For manufacturing IP:

  • crystallization conditions
  • drying and milling parameters
  • solvent selection and impurity profile control
  • specific process steps that map to method claims

Commercial implication

The generic challenger may win legal clearance for active ingredient claims while losing freedom-to-operate on formulation and process patents that remain in force.

Which companies are best positioned to exploit US generic entry windows, and why?

Generic entry success correlates with:

  • a patent challenge track record
  • manufacturing scale and cost advantages
  • litigation bench strength for sustained Paragraph IV challenges
  • payer contracting ability and distribution readiness

Competitive landscape pattern

  • Large multi-product generics: diversify launch risk and can absorb settlement caps.
  • Boutique challengers: focus on high-value claims and narrow segments but carry higher concentration risk.

What revenue exposure do patent expirations create for brand owners, and how do they manage it?

Revenue risk rises as exclusivity windows close and as generics are approved. Brand owners mitigate with:

  • authorized generics (to retain some margin)
  • lifecycle management (new formulations, new indications, new delivery systems)
  • payers’ contracting tools (preemptive rebate redesign, switching restrictions)
  • legal strategy to delay or narrow generic labeling and launch scope

Management tools that affect generic adoption speed

  • narrower carveouts and label controls
  • REMS tightening and patient support routing
  • contracting-based access barriers

How do settlement agreements affect market timing for US generics?

Settlements are often structured around three variables:

  • Launch date: When generic can start marketing.
  • Authorized generic: Whether the branded company sells an authorized generic (reducing challenger volume).
  • Design-around commitments: Whether generics must maintain specific formulations or labeling.

Practical settlement consequences

  • Even after approval, marketing can be delayed by court injunctions or settlement start dates.
  • Authorized generic can reduce the challenged product’s share even if legal clearance is granted.

What FDA compliance challenges can delay launch after legal clearance?

A generic may clear patent barriers yet still face operational delay. Common blockers:

  • labeling finalization and implementation timing
  • REMS establishment or synchronization
  • manufacturing site readiness and inspection outcomes
  • stability, shelf-life approvals, and packaging/batch release constraints
  • post-approval changes requiring prior approval supplements

What are the highest-value regulatory opportunities in the United States for new entrants?

Opportunities cluster in segments where regulatory data packages are feasible and patent estates are attackable:

  • late-stage generic development targeting predictable Hatch-Waxman timing
  • 505(b)(2) bridging where clinical differentiation is achievable
  • formulation improvements that reduce development time while maintaining non-infringing freedom-to-operate
  • biosimilar development for mature biologics where interchangeability adoption is likely to accelerate

Highest signal opportunity areas

  • products with fewer device-like constraints and fewer REMS dependencies
  • assets where Orange Book listings show patent overbreadth (composition claims not tied to actual product features)
  • indications with established payer acceptance and broad substitution history

How do US regulations and patent law interact to create litigation-heavy entry environments?

The entry model links FDA approval schedules to patent litigation timelines. The result is an investment environment where:

  • “approval” can occur before “launch”
  • injunctions and settlement timing determine commercial outcome
  • exclusivity can override patent clearance

Litigation and regulatory timing mechanics that drive commercial strategy

  • court schedules and stay orders influence whether launch is delayed beyond expected exclusivity windows
  • information exchange in biosimilar proceedings can accelerate or delay discovery
  • compliance steps can turn legal clearance into a practical launch-late scenario

Key takeaways

  • Branded spending remains concentrated; generics dominate units and drive substitution, but launch outcomes hinge on Orange Book listings, exclusivity, and litigation.
  • Patent estates are increasingly layered across formulation, solid-state, manufacturing process, and method-of-use, raising freedom-to-operate risk beyond the lead composition patents.
  • Hatch-Waxman Paragraph IV challenges create entry windows, but settlement structures (authorized generics, launch-date scheduling, and scope limits) often determine realized revenue more than courtroom outcomes.
  • FDA exclusivity and label/REMS constraints can block or slow entry even when patent barriers fall.
  • Highest regulatory opportunity concentrates in segments where applicants can both clear IP and execute fast, compliant manufacturing and labeling transitions.

FAQs

1) What is the Orange Book mechanism for identifying relevant patents for generic entry?

Orange Book lists patent numbers tied to the RLD’s drug substance, drug product, and approved uses; a generic must certify against each listed patent for its Paragraph IV strategy.

2) Can a generic be approved before patent expiry in the US?

Yes, FDA approval can occur while patents are still in force if the applicant pursues Paragraph IV, but marketing launch is typically blocked until patent litigation and any related injunctions or settlement terms permit.

3) How does pediatric exclusivity extend US drug exclusivity and affect generics?

Pediatric exclusivity can add up to six months to certain patent-related exclusivity, extending the time before eligible generics can launch.

4) What is the key difference between biosimilar entry and generic entry in the US?

Biosimilar development follows BPCIA evidentiary and “patent dance” rules, and exclusivity and substitution can depend on interchangeability designation, unlike the Orange Book-driven generic framework.

5) What operational issues most commonly delay generic launches after legal clearance?

Label implementation, REMS compliance, manufacturing site readiness, inspection outcomes, stability and shelf-life readiness, and packaging/batch release can delay commercialization even after legal clearance.

References

  1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
  2. U.S. Food and Drug Administration. Hatch-Waxman Act: Drug Competition and Patent Term Restoration Act. FDA.
  3. U.S. Food and Drug Administration. Drug Development and Drug Interactions: 505(b)(2) and generic drug pathways (FDA guidance and informational resources). FDA.
  4. U.S. Food and Drug Administration. Exclusivity for Drugs: Marketing Authorization and Exclusivity. FDA.
  5. U.S. Food and Drug Administration. Biosimilars: Scientific and Regulatory Considerations (BPCIA overview). FDA.

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links